Clinical Trials Logo
  1. Home
  2. CMV
  3. NCT01769170

A Study of the Safety and Efficacy of CMX001 for the Prevention of CMV Infection in CMV-seropositive HCT Recipients

CMV Clinical Trial

Official title:
A Phase 3 Study of the Safety, Tolerability, and Efficacy of CMX001 for the Prevention of Cytomegalovirus (CMV) Infection in CMV-seropositive (R+) Hematopoietic Stem Cell Transplant Recipients

Clinical Trial Summary

This randomized, double-blind, placebo-controlled, parallel group, multicenter study compared the effectiveness of oral brincidofovir (BCV) to placebo for the prevention of cytomegalovirus (CMV) infection in stem cell transplant patients who were CMV seropositive but negative for CMV viremia before starting treatment with BCV.

Clinical Trial Description

This was a randomized, double-blind, placebo-controlled, parallel group multicenter study of oral brincidofovir (BCV) in approximately 450 cytomegalovirus (CMV)-seropositive subjects who had undergone allogeneic hematopoietic stem cell transplantation (HCT). The study consisted of a screening evaluation and a treatment phase of 10 to 14 weeks. Dosing with the study drug (BCV or placebo) was initiated as soon as individual subjects could ingest tablets after transplant but no later than Day 28 post-transplant, and was continued through Week 14. All randomized subjects remained on study and followed the same scheduled study treatment. Study assessments were performed weekly from randomization through completion of the first post-treatment follow-up assessment at Week 15, and every 3 weeks thereafter through Week 24. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01769170
Study type Interventional
Source Chimerix
Contact
Status Completed
Phase Phase 3
Start date August 2013
Completion date January 2016
View Details
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT04101136 - Effect of Atorvastatin on Subclinical Atherosclerosis N/A
Recruiting NCT06001320 - De-novo Initiation of Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis in AA Kidney Trans Recip Early Phase 1
Completed NCT01923766 - Cytotoxic T Cells to Prevent Virus Infections Phase 1
Not yet recruiting NCT05969743 - Letermovir Prophylaxis for Cytomegalovirus (CMV) in Patients With Graft-versus-host Disease Phase 2
Recruiting NCT01011712 - The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Known Immunocompromise
Recruiting NCT06034925 - Maribavir vs. Valganciclovir for CMV Prophylaxis in High-Risk Kidney Transplant Recipients Phase 4
Completed NCT04840199 - A Study to Evaluate the Anti-inflammatory Effects of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive Antiretroviral Therapy, Plus Its Effect on Chronic Inflammation, HIV Persistence and Other Clinical Outcomes. Phase 2
Terminated NCT03502161 - Clinical Evaluation of the QuantiFERON CMV Assay
Not yet recruiting NCT06211543 - Letermovir (LMV) Prophylaxis in CMV-seronegative Allogeneic Stem Cell Transplant Recipients With CMV Seropositive Donors: an Exploratory Study From Spanish GETH/TC Centers
Recruiting NCT04056533 - Prophylaxis of Cytomegalovirus Infection With Adoptive Cell Inmunotherapy Phase 2
Not yet recruiting NCT04280380 - Cytomegalovirus Infection in Critically Ill Patients and Patients Receiving Anticancer Therapy
Active, not recruiting NCT03924219 - CMV T Cell Immunity in Pediatric Solid Organ Transplant Recipients
Not yet recruiting NCT06453460 - Prospect Eval of Efficacy of CMV-TCIP Direct Letermovir Prophylax After Allogen Hemato Cell Transpla Phase 2
Completed NCT02694484 - Search Cytomegalovirus in Healthy Volunteers Stools Samples Selected as Potential Donor for Fecal Microbiota Transplant N/A
Recruiting NCT06011486 - Expansion of Virus-Specific Lymphocytes for Cell Therapy Phase 1
Recruiting NCT04017962 - A Study of the Drug Letermovir (LTV) as Prevention for Recurrent of Cytomegalovirus (CMV) Infection Phase 2
Terminated NCT03570411 - Evaluating the Clinical Utility of the T-SPOT.CMV Assay for the Prediction of CMV Reactivation Among Pediatric Patients Undergoing Hematopoietic Cell Transplant
Enrolling by invitation NCT04392297 - Clinical and Immunological Features of the CMV Infection Atypical Course in Immunocompetent Individuals
Completed NCT00872703 - Does Normal Brain Imaging Predict Normal Neurodevelopmental Outcome in Fetuses With Proven Cytomegalovirus Infection? N/A
Active, not recruiting NCT01945814 - Allogeneic Multivirus - Directed Cytotoxic T Lymphocytes (CTL) Phase 1